Richard Porter
Technik-/Wissenschafts-/F&E-Leiter bei UNIQURE N.V.
Vermögen: 150 801 $ am 30.04.2024
Aktive Positionen von Richard Porter
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
UNIQURE N.V. | Technik-/Wissenschafts-/F&E-Leiter | 05.10.2023 | - |
Corporate Officer/Principal | 01.04.2022 | 05.10.2023 |
Karriereverlauf von Richard Porter
Ehemalige bekannte Positionen von Richard Porter
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Therachon AG | Geschäftsführer | 01.07.2016 | 01.07.2019 |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2014 | 01.08.2016 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 01.09.2011 | 01.02.2014 |
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Direktor/Vorstandsmitglied | 01.11.2019 | - |
Vorstandsvorsitzender | 01.11.2019 | - | |
Gründer | 01.11.2019 | - |
Ausbildung von Richard Porter
The University of Southampton | Doctorate Degree |
Statistik
International
Vereinigtes Königreich | 3 |
Schweiz | 3 |
Frankreich | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Director/Board Member | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
UNIQURE N.V. | Health Technology |
Private Unternehmen | 4 |
---|---|
Corlieve Therapeutics SAS
Corlieve Therapeutics SAS Pharmaceuticals: MajorHealth Technology Corlieve Therapeutics SAS provides neurology services. The company was founded by Richard Porter, Valerie Crepel and Christophe Mulle in November 2019 and is headquartered in Paris, France. | Health Technology |
Therachon AG | |
Roche Group
Roche Group Real Estate DevelopmentFinance Roche Group manages real estate properties. The company designs, develops and constructs residential, commercial and industrial properties. It also provides property management services. The company is headquartered in Basel, Switzerland. | Finance |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
- Börse
- Insiders
- Richard Porter
- Erfahrung